Conference Coverage

ADA: Family-focused diabetes program shows benefits for African American patients


 

AT THE ADA ANNUAL SCIENTIFIC SESSIONS

References

The National Institutes of Health–National Institute on Minority and Health Disparities supported the study.

sworcester@frontlinemedcom.com

Pages

Recommended Reading

ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide
Type 2 Diabetes ICYMI
AACE: Saroglitazar found safe, effective for management of diabetic dyslipidemia
Type 2 Diabetes ICYMI
ELIXA Trial: No Cardiovascular Risk With GLP-1 Receptor Agonist Lixisenatide
Type 2 Diabetes ICYMI
ATS: Metformin failed to improve outcomes after COPD exacerbations
Type 2 Diabetes ICYMI
ADA: Study shows not all children with type 1 diabetes require annual celiac rescreening
Type 2 Diabetes ICYMI
ADA: Stress may up risk for excess gestational weight gain
Type 2 Diabetes ICYMI
ADA: Staying fit helps prevent advanced kidney disease in type 2 diabetes
Type 2 Diabetes ICYMI
ADA: Thiazolidinediones, sulfonylureas best DPP-4s for metformin-based dual GLT
Type 2 Diabetes ICYMI
ADA: Study Shows Not All Children With Type 1 Diabetes Require Annual Celiac Rescreening
Type 2 Diabetes ICYMI
Outcomes and Medication Use in a Longitudinal Cohort of Type 2 Diabetes Patients, 2006 to 2012
Type 2 Diabetes ICYMI